Wellmark Blue Cross and Blue Shield has the fourth-lowest rate of members who have been diagnosed with opioid-use disorder among Blue Cross Blue Shield companies, according to a new report. Among Wellmark members, 3 in 1,000 had that diagnosis last year, compared with 5.9 in 1,000 Blue Cross Blue Shield members nationally, according to “The Opioid Epidemic in America: An Update” conducted by Blue Cross Blue Shield. The rate of opioid prescriptions written for Wellmark members decreased by 30 percent between 2013 and 2017, the report showed. “While we are encouraged by the findings in this report, we can’t lose sight that opioid addiction is still an issue in the state,” said Matt Hosford, Wellmark vice president and chief pharmacy officer. “Wellmark is committed to working with Iowa stakeholders to address this crisis.” Nationally, 241,900 BCBS members were diagnosed with opioid use disorder in 2017.